Idelvion Approved for Hemophilia B
Replaces deficient clotting factor (Source: U.S. News - Health)
Source: U.S. News - Health - March 7, 2016 Category: Consumer Health News Source Type: news

Idelvion Approved for Hemophilia B
MONDAY, March 7, 2016 -- Idelvion has been approved by the U.S. Food and Drug Administration to replace a deficient blood clotting factor among people with hemophilia B. The product -- which has the generic name of "coagulation Factor IX, albumin... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 7, 2016 Category: Journals (General) Source Type: news

Baxalta doses first patient in Phase I trial of BAX 826 to treat haemophilia A
US-based biopharmaceutical firm Baxalta has begun its Phase I clinical trial evaluating BAX 826, a recombinant Factor VIII (rFVIII) treatment for haemophilia A. (Source: Drug Development Technology)
Source: Drug Development Technology - March 7, 2016 Category: Pharmaceuticals Source Type: news

Hemophilia B Treatment Approved (FREE)
By Kristin J. Kelley Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH The FDA has approved the first coagulation factor-albumin fusion protein (marketed as Idelvion) to … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - March 7, 2016 Category: Primary Care Source Type: news

FDA Approves Idelvion for Hemophilia BFDA Approves Idelvion for Hemophilia B
This combination of factor IX and albumin makes the drug last longer in the bloodstream, potentially requiring fewer injections than unmodified clotting factor. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 5, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

'Black death' offers clues to battling HIV, hepatitis C centuries later
The Black Death swept Europe in the 14th century eliminating up to half of the population but it left genetic clues that now may aid a researcher in treating HIV patients co-infected with hepatitis C using an anti-retroviral drug therapy. A new study will look at the blood samples of nearly 3,000 patients, primarily individuals with hemophilia, who were exposed to HIV during the early 1980s and late 1990s, to see if an inherited genetic variant that protects against HIV might also help prevent injury from Hepatitis C and other liver diseases. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 4, 2016 Category: Science Source Type: news

FDA approves first coagulation factor-albumin fusion protein to treat patients with hemophilia B
The U.S. Food and Drug Administration today approved Idelvion, Coagulation Factor IX (Recombinant), Albumin Fusion Protein, for use in children and adults with Hemophilia B. Idelvion is the first coagulation factor-albumin fusion protein product to be approved, and the second Factor IX fusion protein product approved in the U.S. that is modified to last longer in the blood. (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 4, 2016 Category: American Health Source Type: news

FDA Approves Idelvion (coagulation factor IX (recombinant), albumin fusion protein) to Treat Patients with Hemophilia B
March 4, 2016 -- The U.S. Food and Drug Administration today approved Idelvion, Coagulation Factor IX (Recombinant), Albumin Fusion Protein, for use in children and adults with Hemophilia B. Idelvion is the first coagulation factor-albumin fusion... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 4, 2016 Category: Drugs & Pharmacology Source Type: news

Dr. Holbrook Kohrt, Hemophiliac Who Made the Condition a Crusade, Dies at 38
Inspired by his own body’s ability to suppress disease, Dr. Kohrt pursued a medical career that coupled basic science with a clinical practice. (Source: NYT Health)
Source: NYT Health - March 1, 2016 Category: Consumer Health News Authors: SAM ROBERTS Tags: Stanford University Deaths (Obituaries) Kohrt, Holbrook E Hemophilia Immune System Source Type: news

OPKO begins dosing in Phase IIa trial of Factor VIIa-CTP to treat hemophilia
US-based OPKO Health has started dosing in a Phase IIa dose escalation trial to evaluate the safety of a long-acting Factor VIIa to treat patients with hemophilia. (Source: Drug Development Technology)
Source: Drug Development Technology - February 24, 2016 Category: Pharmaceuticals Source Type: news

EU approves Bayer's Kovaltry for haemophilia A
FRANKFURT (Reuters) - The European Commission has approved Bayer's haemophilia A drug Kovaltry for the treatment of patients from all age groups, the company said on Monday. (Source: Reuters: Health)
Source: Reuters: Health - February 22, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Bayer Receives EU Approval of Kovaltry® for Treatment of Hemophilia A (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - February 22, 2016 Category: Pharmaceuticals Source Type: news

Hemophilia Patient or Drug Seller? Dual Role Creates Ethical Quandary
When hemophiliacs make their living by selling lucrative hemophilia drugs, patient advocates say it creates a dangerous conflict of interest. (Source: NYT Health)
Source: NYT Health - January 13, 2016 Category: Consumer Health News Authors: ANDREW POLLACK Tags: Ethics and Official Misconduct Drugs (Pharmaceuticals) Novo Nordisk A/S National Hemophilia Foundation Blood MedfusionRx Pfizer Inc Baxalta Bayer AG Hemophilia of North Carolina Conflicts of Interest Source Type: news

Hemophilia: New Treatments for an Old Disease
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - January 13, 2016 Category: Journals (General) Source Type: news

Hemophilia: New Treatments for an Old Disease
Treating hemophilia can be time-consuming and troublesome. But several newly approved medications, while far from a cure, aim to lift some of that burden. WebMD has the details. (Source: WebMD Health)
Source: WebMD Health - January 12, 2016 Category: Consumer Health News Source Type: news

Sobi(TM) announces commercial launch of Elocta® in first countries in Europe
Swedish Orphan Biovitrum AB announced the commercial launch of Elocta® in first countries in Europe (Source: Pharmacy Europe)
Source: Pharmacy Europe - January 11, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Haematology Patient care elocta haemophilia a Latest News recombinant human factor VIII Fc fusion protein Source Type: news

FDA Announces New Blood Donation Policy for MSM
(MedPage Today) -- FDA adopts looser policy for men who have sex with men, continues deferral for hemophiliacs (Source: MedPage Today Ophthalmology)
Source: MedPage Today Ophthalmology - December 21, 2015 Category: Opthalmology Source Type: news

EMA Panel Backs Two Octocog Alfa Products for Hemophilia A EMA Panel Backs Two Octocog Alfa Products for Hemophilia A
Iblias and Kovaltry from Bayer Pharma AG are indicated for treatment and prevention of bleeding in patients with hemophilia A. International Approvals (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - December 19, 2015 Category: Internal Medicine Tags: Hematology-Oncology News Alert Source Type: news

Bayer Receives Positive CHMP Opinion for BAY 81-8973 for the Treatment of Hemophilia A in Patients in EU (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - December 18, 2015 Category: Pharmaceuticals Source Type: news

Why Is It Called Christmas Disease?
Discussion Too much or too little causes the important homeostatic balance of life to be upset. This is true of the interactions between the circulatory and hematology systems of the body and their important function in ensuring that the circulatory system plumbing is not leaking (i.e. bleeding) and also not getting plugged up (i.e. thrombosis). A healthy system has adequate numbers of functional platelets, and protein synthesis of the factors needed for a balanced hemostasis system. An adequate amount of Vitamin K is needed for some factors activity. Additionally the absence of any drugs that interfere with platelets or t...
Source: PediatricEducation.org - December 14, 2015 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Antibody for severe hemophilia a may reduce injections needed to prevent bleeding
An antibody engineered to prevent excessive bleeding in patients with severe hemophilia A may be safe and effective, and require fewer injections than existing options, according to a first-in-human study of the treatment. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 1, 2015 Category: Science Source Type: news

Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-FIX, First In Vivo Protein Replacement Platform Program For Treatment Of Hemophilia B
Study, Scheduled to Begin in 2016, Will Represent First Clinical Application of In Vivo Genome Editing RICHMOND, Calif., Dec. 1, 2015 -- (Healthcare Sales & Marketing Network) -- Sangamo BioSciences, Inc. (SGMO), the leader in therapeutic genome editin... Biopharmaceuticals, FDASangamo BioSciences, SB-FIX, hemophilia B, genome editing, IVPRP (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 1, 2015 Category: Pharmaceuticals Source Type: news

Study: Antibody for severe hemophilia a may reduce injections needed to prevent bleeding
(American Society of Hematology) An antibody engineered to prevent excessive bleeding in patients with severe hemophilia A may be safe and effective, and require fewer injections than existing options, according to a first-in-human study of the treatment published online today in Blood, the Journal of the American Society of Hematology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 1, 2015 Category: Global & Universal Source Type: news

Elocta Approved in Europe for Hemophilia AElocta Approved in Europe for Hemophilia A
The European Commission has approved Elocta for the treatment of hemophilia A in all 28 European Union member states, Iceland, Liechtenstein, and Norway. International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 26, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Baxalta seeks UK MHRA approval for BAX 826 trial of to treat hemophilia A
US-based biopharmaceutical firm Baxalta has submitted a clinical trial application (CTA) to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) seeking approval to start a first-in-human clinical trial of BAX 826, an investigational, ex… (Source: Drug Development Technology)
Source: Drug Development Technology - November 23, 2015 Category: Pharmaceuticals Source Type: news

Baxalta Gets FDA Approval for State-of-the-Art Singapore Facility
Baxalta announced that its state-of-the-art recombinant biologic manufacturing facility in Singapore received U.S. FDA approval to manufacture bulk drug substance for Advate, Baxalta’s market leading treatment for hemophilia A. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 18, 2015 Category: Pharmaceuticals Source Type: news

Baxalta receives European approval for Obizur to treat haemophilia A
(Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - November 16, 2015 Category: Pharmaceuticals Source Type: news

Recombinant Hemophilia A Product OK'd
(MedPage Today) -- FDA approves pegylated Factor VIII agent (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 14, 2015 Category: Hematology Source Type: news

FDA Approves Adynovate for Hemophilia AFDA Approves Adynovate for Hemophilia A
The therapeutic reduced bleeding episodes and controlled them once they started. FDA Approvals (Source: Medscape Pediatrics Headlines)
Source: Medscape Pediatrics Headlines - November 14, 2015 Category: Pediatrics Tags: Hematology-Oncology News Alert Source Type: news

FDA approves modified antihemophilic factor for hemophilia A
The U.S. Food and Drug Administration today approved Adynovate, Antihemophilic Factor (Recombinant), PEGylated for use in adults and adolescents, aged 12 years and older, who have Hemophilia A. Adynovate is modified to last longer in the blood and potentially require less frequent injections than unmodified Antihemophilic Factor when used to reduce the frequency of bleeding. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 13, 2015 Category: American Health Source Type: news

Pfizer: Think patient-first when developing mobile health apps
NYC-based pharma company Pfizer currently has 15 apps in the US iOS app store, ranging from a chapstick companion app to an app for people with kidney cancer. At the HIMSS Connected Health Summit in National Harbor, Maryland, Pfizer executives talked about two of the company’s apps and their broader strategy for developing mobile health interventions. […] (Source: mobihealthnews)
Source: mobihealthnews - November 9, 2015 Category: Information Technology Authors: Jonah Comstock Tags: Pharma HemMobile hemophilia mobile health apps Pfizer Quitter's Circle smoking cessation Source Type: news

Roche showcases pharmaceuticals strategy and emerging new medicines
Roche is today providing an update on its late-stage pipeline at an investor event in London, including promising investigational medicines for multiple sclerosis, asthma, haemophilia, eye disease and cancer. In these and other areas, Roche expects as many as seven major read-outs from clinical trials with new molecular entities or line extensions for existing medicines up to the end of 2017, adding to the seven read-outs already achieved in 2015. (Source: Roche Investor Update)
Source: Roche Investor Update - November 5, 2015 Category: Pharmaceuticals Source Type: news

The Man Who Grew Eyes
The train line from mainland Kobe is a marvel of urban transportation. Opened in 1981, Japan’s first driverless, fully automated train pulls out of Sannomiya station, guided smoothly along elevated tracks that stand precariously over the bustling city streets below, across the bay to the Port Island. The island, and much of the city, was razed to the ground in the Great Hanshin Earthquake of 1995 – which killed more than 5,000 people and destroyed more than 100,000 of Kobe’s buildings – and built anew in subsequent years. As the train proceeds, the landscape fills with skyscrapers. The Rokkō mounta...
Source: Healthy Living - The Huffington Post - October 11, 2015 Category: Consumer Health News Source Type: news

The Man Who Grew Eyes
The train line from mainland Kobe is a marvel of urban transportation. Opened in 1981, Japan’s first driverless, fully automated train pulls out of Sannomiya station, guided smoothly along elevated tracks that stand precariously over the bustling city streets below, across the bay to the Port Island. The island, and much of the city, was razed to the ground in the Great Hanshin Earthquake of 1995 – which killed more than 5,000 people and destroyed more than 100,000 of Kobe’s buildings – and built anew in subsequent years. As the train proceeds, the landscape fills with skyscrapers. The Rokkō mounta...
Source: Science - The Huffington Post - October 11, 2015 Category: Science Source Type: news

Hemophilia A Drugs Market See 6% CAGR Growth and Hemophilia B Market...
The Global Hemophilia A Market 2015-2019 and Global Hemophilia B Market 2015-2019 - Industry Analysis reports are new Pharmaceuticals industry research added to ReportsnReports.com store.(PRWeb October 07, 2015)Read the full story at http://www.prweb.com/releases/Drugs-hemophilia-a-and/hemophilia-b-market-2019/prweb13008170.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 8, 2015 Category: Pharmaceuticals Source Type: news

Roche, Voluntis to co-develop mobile-enabled therapy for breast cancer
French medical app company Voluntis is partnering with Roche Pharma France, a subsidiary of Roche, to develop a mobile-based therapy for breast cancer. Voluntis makes companion apps for medical devices. It has so far focused on the areas of diabetes, hemophilia, and coagulation. Voluntis actually worked with Roche Diagnostics in the past, on a companion software for Roche’s CoaguChek […] (Source: mobihealthnews)
Source: mobihealthnews - September 30, 2015 Category: Information Technology Authors: Jonah Comstock Tags: Pharma breast cancer Diabetes Glooko oncology Roche Roche Diagnostics Roche Pharma France Voluntis Source Type: news

Penn Dental Medicine study is proof-of-concept for low-cost drug made in lettuce
(University of Pennsylvania) At the University of Pennsylvania School of Dental Medicine, Henry Daniell and colleagues have used a plant-based system to make shelf-stable drugs. In a study published in the journal Biomaterials, the researchers confirmed the viability of their method for FDA approval and human use, producing an effective drug that promotes tolerance to clotting factors, which could be taken by hemophilia patients, using freeze-dried lettuce leaves. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 30, 2015 Category: Global & Universal Source Type: news

Nuwiq, Anti-Haemophilic Factor (recombinant) for the Treatment of Haemophilia A
Nuwiq injection is the first recombinant anti-haemophilic factor (blood coagulation factor VIII) drug indicated for the treatment of patients with haemophilia A. (Source: Drug Development Technology)
Source: Drug Development Technology - September 23, 2015 Category: Pharmaceuticals Source Type: news

FDA Clears Hemophilia A Drug NuwiqFDA Clears Hemophilia A Drug Nuwiq
The intravenous antihemophilic factor is for on-demand treatment and routine prophylaxis of bleeding in adults and children with hemophilia A. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 16, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

No silver jubilee for Queen Victoria | Letters
Queen Victoria did not enjoy a silver jubilee (Who is the UK’s queen of queens?, 5 September). Apart from her not being in a condition to enjoy anything in 1862, a few months after Prince Albert’s death, the concept was unknown. “Jubilee” still meant a 50-year event, as in Leviticus, or an occasional year decreed by the pope for particular purposes. The first royal “silver jubilee” was that of Kaiser Wilhelm I in 1886; the next noted by the Times was that of the King of Siam in 1893; the first British royal “silver jubilee” was that of George V in 1935.Charles Gordon Cla...
Source: Guardian Unlimited Science - September 14, 2015 Category: Science Authors: Letters Tags: Monarchy Queen Victoria UK news Genetics Biology Science Source Type: news

Roche hemophilia drug wins fast-track FDA designation
ZURICH (Reuters) - Roche said on Friday it had won breakthrough therapy designation from the U.S. Food and Drug Administration for an experimental hemophilia medicine, aiming for a piece of the $11 billion hemophilia drug market. (Source: Reuters: Health)
Source: Reuters: Health - September 4, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

US FDA grants breakthrough therapy designation for Roche's investigational medicine ACE910 for people with haemophilia A with factor VIII inhibitors
Roche today announced that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to ACE910 (RG6013, RO5534262) for the prophylactic treatment of people who are 12 years or older with haemophilia A with factor VIII inhibitors. (Source: Roche Media News)
Source: Roche Media News - September 4, 2015 Category: Pharmaceuticals Source Type: news

US FDA grants breakthrough therapy designation for Roche's investigational medicine ACE910 for people with haemophilia A with factor VIII inhibitors
Roche today announced that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to ACE910 (RG6013, RO5534262) for the prophylactic treatment of people who are 12 years or older with haemophilia A with factor VIII inhibitors. (Source: Roche Investor Update)
Source: Roche Investor Update - September 4, 2015 Category: Pharmaceuticals Source Type: news

Cancer, transplant patients protest over Venezuela's medicine shortages
CARACAS (Reuters) - Venezuelans with chronic medical conditions such as breast cancer, hemophilia and transplants protested in Caracas on Thursday, the latest demonstration to demand urgent medicines in a country beset with shortages. (Source: Reuters: Health)
Source: Reuters: Health - August 28, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

Cancer, transplant patients protest Venezuela's medicine shortages
CARACAS (Reuters) - Venezuelans with chronic medical conditions such as breast cancer, hemophilia and transplants protested in Caracas on Thursday, the latest demonstration to demand urgent medicines in a country whose health care system is beset with shortages. (Source: Reuters: Health)
Source: Reuters: Health - August 27, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

CSL Behring begins rVIIa-FP Phase II / III trial for haemophilia A or B
Biopharmaceutical firm CSL Behring has started the Phase II / III clinical trial, which has been designed to assess the recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP or CSL689) to treat patients with congenital hae… (Source: Drug Development Technology)
Source: Drug Development Technology - August 26, 2015 Category: Pharmaceuticals Source Type: news

Sobi and Biogen release interim results from the B-YOND study
Results from B-YOND study reinforce long-term clinical profile of Alprolix for the treatment of haemophilia B (Source: Pharmacy Europe)
Source: Pharmacy Europe - August 18, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Other conferences & symposia Haematology Latest News Source Type: news

Kids' Hemophilia Drugs a Big Part of State Medicaid Spending
Title: Kids' Hemophilia Drugs a Big Part of State Medicaid SpendingCategory: Health NewsCreated: 7/31/2015 12:00:00 AMLast Editorial Review: 8/3/2015 12:00:00 AM (Source: MedicineNet Kids Health General)
Source: MedicineNet Kids Health General - August 3, 2015 Category: Pediatrics Source Type: news